ANI Pharmaceuticals Inc

ANIP

$41.93

+33.3% last 12 months

Market Cap

$710 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$26.10 - $60.23

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-32.12x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $710 Million
Enterprise Value $897 Million
Dividend Yield $0.00 (0.0%)
1 Year Return +33.3%
52-Week High $60.23
52-Week Low $26.10
Beta 1.23
Outstanding Shares 16.7 Million
Avg 30 Day Volume 147 Thousand

Valuation

P/E Ratio -32.12
PEG 2.86
Earnings per Share -$1.83
Price to Sales Ratio 3.49
Price to Book Ratio 3.81
Revenue to Enterprise Value 4.22
EBIT to Enterprise Value -286.96
Total Debt to Enterprise Value 0.23
Debt to Equity 1.06

Profitability

Revenue $212 Million
Gross Profit $121 Million
EBIT -$3.13 Million
Net Income -$22.1 Million
Profit Margin -10.4%
Quarterly Earnings Growth (YoY) -1124.7%
Return on Equity -11.55%
Return on Assets -4.7%
Return on Invested Capital -0.81%

Insider trades

No purchases

No sells

No purchases

No sells

6,572 shares bought (3 transactions)

No sells

No purchases

No sells

Q2 2021 Q3 2021 Q4 2021 Q1 2022

About ANI Pharmaceuticals Inc

CEO: Patrick Walsh

Industry: Biological Product (except Diagnostic) Manufacturing

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

Similar stocks

Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc
Evoke Pharma Inc
Evoke Pharma Inc
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Infinity Pharmaceuticals Inc.
Infinity Pharmaceuticals Inc.
Pfizer Inc.
Pfizer Inc.
Lannett Co., Inc.
Lannett Co., Inc.
Celldex Therapeutics Inc.
Celldex Therapeutics Inc.
Cardinal Health, Inc.
Cardinal Health, Inc.
Novartis AG - ADR
Novartis AG - ADR
Royalty Pharma plc - Class A
Royalty Pharma plc - Class A

News